Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

86P - Plasma exosomal AKR1C3 mRNA expression is a predictive and prognostic biomarker in metastatic castration-resistant prostate cancer patients

Date

10 Sep 2022

Session

Poster session 01

Topics

Tumour Site

Prostate Cancer

Presenters

Sha Zhu

Citation

Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037

Authors

S. Zhu1, Y. Ni2, G. Sun3, H. Zeng1

Author affiliations

  • 1 Urology, West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 2 Urology, West China School of Medicine/West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 3 Department Of Urology, West China Hospital of Sichuan University, 610041 - Chengdu/CN
More

Abstract 86P

Background

Aldo-keto reductase family 1 member C3 (AKR1C3) is important in prostate cancer progression, being a potential biomarker in metastatic castration-resistant prostate cancer (mCRPC). Previous explorations of AKR1C3 are mainly based on tissue samples. This study investigates using plasma-based liquid biopsy to validate the prognostic and predictive value of AKR1C3 in mCRPC patients.

Methods

We prospectively recruited 62 mCRPC patients. All patients received repeated prostate biopsies at the time of mCRPC diagnosis, and immunohistochemistry (IHC) staining was used to detect protein expression of AKR1C3 in the tissues. We took their blood simultaneously and performed digital droplet polymerase chain reaction (ddPCR) to measure expression levels of AKR1C3 in the exosomes. The detected plasma and tissue AKR1C3 expression levels were analyzed for patients’ overall survival (OS) and progression-free survival under first-line abiraterone use (ABI-PFS).

Results

All other baseline characteristics were balanced between the two groups. 15/62 (24.2%) and 25/62 (40.3%) patients showed AKR1C3-EXO positive (≥20 copies/20 μL) and AKR1C3-IHC positive, respectively. Positive AKR1C3-EXO expression was associated with decreased patients’ survival [ABI-PFS: 3.9 vs. 10.1 months, P<0.001; OS: 16.2 vs. 32.5 months, P<0.001]. AKR1C3-IHC positivity was also correlated with ABI-PFS and OS (P=0.010, P=0.016). In patients with worse baseline blood tests (including higher alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) level and lower hemoglobin (HB) level), and lower ISUP/WHO group (<4), their OS was significantly worse when showing AKR1C3-EXO positive.

Conclusions

AKR1C3-EXO is associated with patient prognosis regarding OS and ABI-PFS and can be used as a biomarker in mCRPC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The Natural Science Foundation of China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.